172 related articles for article (PubMed ID: 18283195)
1. Severe purpuric xerotic dermatitis associated with gefitinib therapy.
Sheen YS; Hsiao CH; Chu CY
Arch Dermatol; 2008 Feb; 144(2):269-70. PubMed ID: 18283195
[No Abstract] [Full Text] [Related]
2. Livedo reticularis with retiform purpura associated with gefitinib (Iressa).
Blume JE; Miller CC
Int J Dermatol; 2007 Dec; 46(12):1307-8. PubMed ID: 18173531
[No Abstract] [Full Text] [Related]
3. Purpuric drug eruption possibly due to gefinitib (Iressa).
Kurokawa I; Endo K; Hirabayashi M
Int J Dermatol; 2005 Feb; 44(2):167-8. PubMed ID: 15689221
[No Abstract] [Full Text] [Related]
4. Rare cutaneous side-effect of gefitinib masquerading as superficial dermatophytosis.
Lin SS; Tsai TH; Yang HH
Clin Exp Dermatol; 2009 Jun; 34(4):528-30. PubMed ID: 19196304
[No Abstract] [Full Text] [Related]
5. Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer.
Shih HC; Hsiao YP; Wu MF; Yang JH
Br J Dermatol; 2006 Nov; 155(5):1101-2. PubMed ID: 17034565
[No Abstract] [Full Text] [Related]
6. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
7. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
8. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Acharyya S; Sau S; Dasgupta P; Chakraborty A; Gangopadhyay S
J Indian Med Assoc; 2012 Jul; 110(7):474-6, 493. PubMed ID: 23520673
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib-associated dermatological toxicity.
Mumoli N; Cei M; Vitale J
QJM; 2013 Apr; 106(4):363-4. PubMed ID: 22927541
[No Abstract] [Full Text] [Related]
10. Erlotinib-induced skin manifestations.
Motoki T; Mitsuishi T; Kawana S
J Dermatol; 2009 Dec; 36(12):658-9. PubMed ID: 19958452
[No Abstract] [Full Text] [Related]
11. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
Seiverling EV; Fernanadez EM; Adams D
J Drugs Dermatol; 2006 Apr; 5(4):368-9. PubMed ID: 16673807
[TBL] [Abstract][Full Text] [Related]
12. APL during gefitinib treatment for non-small-cell lung cancer.
Uchida A; Matsuo K; Tanimoto M
N Engl J Med; 2005 Feb; 352(8):843. PubMed ID: 15728826
[No Abstract] [Full Text] [Related]
13. Erlotinib induced target-like purpura.
Rungtrakulchai R; Rerknimitr P
Dermatol Online J; 2014 Feb; 20(2):. PubMed ID: 24612572
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.
Wang MZ; Li LY; Wang SL; Zhang XT; Zhong W; Zhang L
Chin Med J (Engl); 2006 Jan; 119(1):63-8. PubMed ID: 16454984
[No Abstract] [Full Text] [Related]
15. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.
Nagaria NC; Cogswell J; Choe JK; Kasimis B
J Clin Oncol; 2005 Apr; 23(10):2423-4. PubMed ID: 15800334
[No Abstract] [Full Text] [Related]
16. Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
Pascual JC; Belinchón I; Sivera F; Yuste A
Br J Dermatol; 2005 Dec; 153(6):1222-3. PubMed ID: 16307664
[No Abstract] [Full Text] [Related]
17. [Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].
Zhang PL; Chen L
Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):635-6. PubMed ID: 18210890
[No Abstract] [Full Text] [Related]
18. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.
Chang GC; Yang TY; Chen KC; Yin MC; Wang RC; Lin YC
J Clin Oncol; 2004 Nov; 22(22):4646-8. PubMed ID: 15542815
[No Abstract] [Full Text] [Related]
19. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
Graves JE; Jones BF; Lind AC; Heffernan MP
J Am Acad Dermatol; 2006 Aug; 55(2):349-53. PubMed ID: 16844529
[TBL] [Abstract][Full Text] [Related]
20. A severe dermatologic adverse effect related with gefitinib: case report and review of the literature.
Li YQ; Sun H; Xue D
J Cancer Res Ther; 2013 Sep; 9 Suppl 2():S110-3. PubMed ID: 24135241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
